Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key HIV Studies Influencing My Practice Following IDWeek and HIV Glasgow 2022—Audio Recap

Washington, DC - October 19-23, 2022; Glasgow, Scotland and virtual - October 23-26, 2022
Listen to expert insights from Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS, on some of the most clinically relevant new HIV data presented at IDWeek and HIV Glasgow 2022, including prevention strategies, long-acting therapies, and investigational agents.
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Babafemi Taiwo, MBBS
Released: December 5, 2022

In this episode, Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS, discuss new HIV data presented at IDWeek and HIV Glasgow 2022, including

  • Prevention strategies
    • Updated data from HPTN 083 evaluating LA CAB for PrEP in men who have sex with men and transgender women
    • Data on awareness and use of PrEP among cisgender women in the United States
  • LA therapies
    • Data from an expanded multivariable analysis of factors associated with virologic failure of LA CAB + RPV
    • Data from the OPERA cohort on outcomes during the first year of real-world LA CAB + RPV use in the United States
    • Data from the CARLOS cohort on 6-month outcomes of real-world LA CAB + RPV use in Germany
    • Safety, efficacy, and adherence data from the CARISEL phase IIIb implementation study of LA CAB + RPV use in Europe
    • Week 52 efficacy, safety, and lenacapavir resistance data from the CAPELLA trial
  • Investigational agents
    • Post hoc analysis of P011 evaluating dose-dependent islatravir effect on lymphocytes
    • Modeling and simulation study to identify optimal islatravir dosing for clinical development

Information on this Educational Activity


Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead Sciences, Janssen, MSD, ViiV Healthcare; researcher: AstraZeneca, Gilead Sciences, Janssen, MSD, ViiV Healthcare.
Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, ViiV Healthcare.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Kenric Ware discusses opportunities to increase PrEP awareness and uptake on college campuses in this podcast from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: February 1, 2023

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings